132 related articles for article (PubMed ID: 38299685)
41. Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.
Cortes J; Radich J; Mauro MJ
Clin Adv Hematol Oncol; 2012 Oct; 10(10 Suppl 19):1-16. PubMed ID: 23187745
[TBL] [Abstract][Full Text] [Related]
42. Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance.
Rudich A; Garzon R; Dorrance A
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293127
[TBL] [Abstract][Full Text] [Related]
43. Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response.
Mohd Yacob A; Muhamad NA; Chang KM; Akmal Hisham H; Mat Yusoff Y; Ibrahim L
BMC Cancer; 2022 Mar; 22(1):332. PubMed ID: 35346116
[TBL] [Abstract][Full Text] [Related]
44. Immature CML cells implement a BMP autocrine loop to escape TKI treatment.
Grockowiak E; Laperrousaz B; Jeanpierre S; Voeltzel T; Guyot B; Gobert S; Nicolini FE; Maguer-Satta V
Blood; 2017 Dec; 130(26):2860-2871. PubMed ID: 29138221
[TBL] [Abstract][Full Text] [Related]
45. Mechanisms of resistance in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Perekhrestenko T; Diachenko M; Sviezhentseva I; Gordienko A; Bilko D
Georgian Med News; 2015 Mar; (240):43-50. PubMed ID: 25879558
[TBL] [Abstract][Full Text] [Related]
46. miR-181a plays the tumor-suppressor role in chronic myeloid leukemia CD34
Zhang X; Ma W; Xue W; Wang Y; Chen P; Li Q; Li YY; Hu X; Zhao Y; Zhou H
Cell Mol Life Sci; 2023 Dec; 81(1):10. PubMed ID: 38103082
[TBL] [Abstract][Full Text] [Related]
47. Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review.
Al Hamad M
F1000Res; 2021; 10():1288. PubMed ID: 35284066
[TBL] [Abstract][Full Text] [Related]
48. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
[TBL] [Abstract][Full Text] [Related]
49. Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors.
Yaghmaie M; Yeung CC
Curr Hematol Malig Rep; 2019 Oct; 14(5):395-404. PubMed ID: 31463864
[TBL] [Abstract][Full Text] [Related]
50. Role of miRNAs to control the progression of Chronic Myeloid Leukemia by their expression levels.
Bansal M; Ansari S; Verma M
Med Oncol; 2024 Jan; 41(2):55. PubMed ID: 38216843
[TBL] [Abstract][Full Text] [Related]
51. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
[TBL] [Abstract][Full Text] [Related]
52. Exome, transcriptome and miRNA analysis don't reveal any molecular markers of TKI efficacy in primary CML patients.
Lavrov AV; Chelysheva EY; Adilgereeva EP; Shukhov OA; Smirnikhina SA; Kochergin-Nikitsky KS; Yakushina VD; Tsaur GA; Mordanov SV; Turkina AG; Kutsev SI
BMC Med Genomics; 2019 Mar; 12(Suppl 2):37. PubMed ID: 30871622
[TBL] [Abstract][Full Text] [Related]
53. Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.
Scott MT; Korfi K; Saffrey P; Hopcroft LE; Kinstrie R; Pellicano F; Guenther C; Gallipoli P; Cruz M; Dunn K; Jorgensen HG; Cassels JE; Hamilton A; Crossan A; Sinclair A; Holyoake TL; Vetrie D
Cancer Discov; 2016 Nov; 6(11):1248-1257. PubMed ID: 27630125
[TBL] [Abstract][Full Text] [Related]
54. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Shah M; Bhatia R
Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
[TBL] [Abstract][Full Text] [Related]
55. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
56. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
[TBL] [Abstract][Full Text] [Related]
57. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
58. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.
Kaehler M; Cascorbi I
Handb Exp Pharmacol; 2023; 280():65-83. PubMed ID: 36882601
[TBL] [Abstract][Full Text] [Related]
59. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.
Kim T; Tyndel MS; Zhang Z; Ahn J; Choi S; Szardenings M; Lipton JH; Kim HJ; Kim Dong Hwan D
Leuk Res; 2017 Aug; 59():142-148. PubMed ID: 28667884
[TBL] [Abstract][Full Text] [Related]
60. SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia.
Sinnakannu JR; Lee KL; Cheng S; Li J; Yu M; Tan SP; Ong CCH; Li H; Than H; Anczuków-Camarda O; Krainer AR; Roca X; Rozen SG; Iqbal J; Yang H; Chuah C; Ong ST
Leukemia; 2020 Jul; 34(7):1787-1798. PubMed ID: 32051529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
